EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Enhanced Hemocompatibility via Bivalirudin and Bicarbonate as Alternative to Heparin in a Catheter‐Based Axial‐Flow System

Kaitlyn R Ammann iD, Christine E Outridge, Tiana Silver, Sami Muslmani, Jun Ding, Vladimir Gilman, Scott Corbett, Marvin J Slepian

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31663 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Kaitlyn R Ammann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Arizona Center for Accelerated Biomedical Innovation, Sarver Heart Center, University of Arizona Health Sciences, The University of Arizona, Tucson, …. Hauptthemen laut MEDLINE: Hirudins, Heparin, Peptide Fragments, Heart-Assist Devices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was supported by an unrestricted educational grant from Johnson and Johnson/Abiomed Inc as well as from a grant from the Arizona Center for Accelerat….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiovascular therapeutic devices typically require systemic heparin due to underlying thrombotic risk. The Impella axial flow system further relies on internal perfusion with either a heparin‐containing or sodium bicarbonate purge solution during operation. The combination of systemic and device‐mediated heparin often contributes to varying levels of overall anticoagulation, raising the possibility of increased bleeding risk and complications due to heparin sensitivity. To reduce adverse events, efforts have been ongoing to eliminate heparin, both systemically and via the device. Here, we investigate bivalirudin as an alternative to systemic heparin and sodium bicarbonate as an alternative to local device heparin in the purge solution.

Methods

We examined hemocompatibility in a mock loop environment with circulating whole porcine blood to determine feasibility of heparin‐free Impella system. Anticoagulated (heparin or bivalirudin) blood was loaded into a circulatory loop with a contained Impella 5.5 and run for 4 h with either heparin or sodium bicarbonate‐containing purge solution. Blood samples were collected serially and analyzed for metrics of hemocompatibility: hemolysis, platelet activation, and vWF degradation.

Results

Bivalirudin and sodium bicarbonate adjunctive environment led to similar or improved hemocompatibility as compared to heparin‐containing environment—notably, decreased hemolysis (40 ± 20.8 mg/dL average decrease) and preserved platelet activity measured by P‐selectin exposure (8.0 ± 5.6% average increase).

Conclusions

Our data supports the potential to create an overall heparin‐free approach simplifying anticoagulation management, offering potential for overall reduced bleeding risk and heparin‐related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HirudinsHeparinPeptide FragmentsHeart-Assist DevicesSodium BicarbonateAntithrombinsAnticoagulantsCardiac CatheterizationRecombinant ProteinsAnimalsHemolysisMaterials TestingSwinePlatelet ActivationFeasibility StudiesTime FactorsModels, Animal

Stichwörter der Autor:innen

bicarbonatebivalirudinhemocompatibilityheparinmechanical circulatory support

Substanzen

bivalirudinHirudinsHeparinRecombinant ProteinsPeptide FragmentsSodium BicarbonateAntithrombinsAnticoagulants

Autor:innen und Institutionen

  • Arizona Center for Accelerated Biomedical Innovation, Sarver Heart Center, University of Arizona Health Sciences, The University of Arizona, Tucson, Arizona, USA.
  • Abiomed Inc., Danvers, Massachusetts, USA.
  • Department of Medicine, Department of Biomedical Engineering, Arizona Center for Accelerated Biomedical Innovation, Sarver Heart Center, The University of Arizona, Tucson, Arizona, USA.

ORCID-Profile: Kaitlyn R Ammann

Förderung

  • This work was supported by an unrestricted educational grant from Johnson and Johnson/Abiomed Inc as well as from a grant from the Arizona Center for Accelerat…

Zitieren

APA

Ammann, K. R., Outridge, C. E., Silver, T., Muslmani, S., Ding, J., Gilman, V., Corbett, S., & Slepian, M. J. (2025). Enhanced Hemocompatibility via Bivalirudin and Bicarbonate as Alternative to Heparin in a Catheter‐Based Axial‐Flow System. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31663

Vancouver

Ammann KR, Outridge CE, Silver T, Muslmani S, Ding J, Gilman V, et al. Enhanced Hemocompatibility via Bivalirudin and Bicarbonate as Alternative to Heparin in a Catheter‐Based Axial‐Flow System. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31663

BibTeX
@article{Ammann2025,
  author = {Ammann, Kaitlyn R and Outridge, Christine E and Silver, Tiana and Muslmani, Sami and Ding, Jun and Gilman, Vladimir and Corbett, Scott and Slepian, Marvin J},
  title = {Enhanced Hemocompatibility via Bivalirudin and Bicarbonate as Alternative to Heparin in a Catheter‐Based Axial‐Flow System},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31663}
}
Kostenlos starten →